全文获取类型
收费全文 | 25322篇 |
免费 | 2066篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 155篇 |
儿科学 | 972篇 |
妇产科学 | 815篇 |
基础医学 | 3582篇 |
口腔科学 | 447篇 |
临床医学 | 3267篇 |
内科学 | 4788篇 |
皮肤病学 | 367篇 |
神经病学 | 2902篇 |
特种医学 | 412篇 |
外科学 | 2135篇 |
综合类 | 293篇 |
一般理论 | 46篇 |
预防医学 | 3296篇 |
眼科学 | 429篇 |
药学 | 1658篇 |
中国医学 | 44篇 |
肿瘤学 | 1839篇 |
出版年
2023年 | 214篇 |
2022年 | 251篇 |
2021年 | 560篇 |
2020年 | 400篇 |
2019年 | 645篇 |
2018年 | 681篇 |
2017年 | 547篇 |
2016年 | 563篇 |
2015年 | 650篇 |
2014年 | 942篇 |
2013年 | 1262篇 |
2012年 | 1830篇 |
2011年 | 1881篇 |
2010年 | 1024篇 |
2009年 | 979篇 |
2008年 | 1536篇 |
2007年 | 1697篇 |
2006年 | 1688篇 |
2005年 | 1583篇 |
2004年 | 1530篇 |
2003年 | 1434篇 |
2002年 | 1322篇 |
2001年 | 291篇 |
2000年 | 277篇 |
1999年 | 257篇 |
1998年 | 273篇 |
1997年 | 236篇 |
1996年 | 173篇 |
1995年 | 171篇 |
1994年 | 127篇 |
1993年 | 154篇 |
1992年 | 166篇 |
1991年 | 145篇 |
1990年 | 118篇 |
1989年 | 120篇 |
1988年 | 100篇 |
1987年 | 87篇 |
1986年 | 90篇 |
1985年 | 89篇 |
1984年 | 80篇 |
1983年 | 90篇 |
1982年 | 92篇 |
1981年 | 73篇 |
1980年 | 80篇 |
1979年 | 59篇 |
1978年 | 53篇 |
1977年 | 46篇 |
1976年 | 58篇 |
1974年 | 46篇 |
1973年 | 53篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
2.
3.
4.
5.
6.
7.
8.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
9.
Mary Ann Richardson Helen M Chao Laura L Read James D Clelland Raymond F Suckow 《American journal of medical genetics. Part B, Neuropsychiatric genetics》2006,(2):195-197
Phenylketonuria (PKU), an inborn error of phenylalanine metabolism, has been shown to be a risk factor for tardive dyskinesia (TD). In male psychiatric patients there was a significant relationship between TD and measures of plasma phenylalanine following ingestion of a standardized phenylalanine dose that was indicative of higher brain availability of phenylalanine in patients with TD. In addition, a medical food formulation consisting of branched chain amino acids, which compete with phenylalanine for transport across the blood-brain barrier, has been demonstrated to be an efficacious treatment for TD. Cumulatively these findings suggested that TD was related to phenylalanine metabolism and thus that sequence variants in the gene for phenylalanine hydroxylase (PAH), the rate-limiting enzyme in the catabolism of phenylalanine, could be associated with TD susceptibility. Genetic screening of PAH in a group of 123 psychiatric patients revealed ten sequence polymorphisms and two mutations, but none appeared to be a significant risk factor for TD. 相似文献
10.
Alexander Stoff MD ; Angel A. Rivera PhD ; N. S. Banerjee PhD ; J. Michael Mathis PhD ; Antonio Espinosa-de-los-Monteros MD ; Long P. Le PhD ; Jorge I. De la Torre MD ; Luis O. Vasconez MD ; Thomas R. Broker PhD ; Dirk F. Richter MD ; Mariam A. Stoff-Khalili MD ; David T. Curiel MD PhD 《Wound repair and regeneration》2006,14(5):608-617
Genetically modified keratinocytes and fibroblasts are suitable for delivery of therapeutic genes capable of modifying the wound healing process. However, efficient gene delivery is a prerequisite for successful gene therapy of wounds. Whereas adenoviral vectors (Ads) exhibit superior levels of in vivo gene transfer, their transductional efficiency to cells resident within wounds may nonetheless be suboptimal, due to deficiency of the primary adenovirus receptor, coxsackie-adenovirus receptor (CAR). We explored CAR-independent transduction to fibroblasts and keratinocytes using a panel of CAR-independent fiber-modified Ads to determine enhancement of infectivity. These fiber-modified adenoviral vectors included Ad 3 knob (Ad5/3), canine Ad serotype 2 knob (Ad5CAV-2), RGD (Ad5.RGD), polylysine (Ad5.pK7), or both RGD and polylysine (Ad5.RGD.pK7). To evaluate whether transduction efficiencies of the fiber-modified adenoviral vectors correlated with the expression of their putative receptors on keratinocytes and fibroblasts, we analyzed the mRNA levels of CAR, alpha upsilon integrin, syndecan-1, and glypican-1 using quantitative polymerase chain reaction. Analysis of luciferase and green fluorescent protein transgene expression showed superior transduction efficiency of Ad5.pK7 in keratinocytes and Ad5.RGD.pK7 in fibroblasts. mRNA expression of alpha upsilon integrin, syndecan-1 and glypican-1 was significantly higher in primary fibroblasts than CAR. In keratinocytes, syndecan-1 expression was significantly higher than all the other receptors tested. Significant infectivity enhancement was achieved in keratinocytes and fibroblasts using fiber-modified adenoviral vectors. These strategies to enhance infectivity may help to achieve higher clinical efficacy of wound gene therapy. 相似文献